Multiple reports say demand for the newly approved Wegovy pill is increasing quickly. One outlet cites early ordering data from a single provider, indicating that more patients are requesting the tablet than the injectable form at the start of availability. The same reporting notes that some companies are experiencing long waiting lists for GLP-1 weight-loss medicines and raises questions about whether current supplies will be able to keep up with demand.
While the coverage emphasizes the early demand figures—describing the pill as potentially more popular than injections—the reports do not provide broad, nationwide sales totals or confirm market share across all pharmacies. They also do not detail manufacturing capacity, expected delivery timelines, or whether supply constraints differ between the pill and the injection.
Overall, the story centers on early uptake following approval, the comparison of pill versus injection ordering through a provider’s data, and ongoing concerns in the market about maintaining supply as demand grows.
